PUBLISHER: Grand View Research | PRODUCT CODE: 1888694
PUBLISHER: Grand View Research | PRODUCT CODE: 1888694
The global transcatheter heart valve market size was estimated at USD 5.49 billion in 2024 and projected to reach USD 21.24 billion by 2033, growing at a CAGR of 16.49% from 2025 to 2033. The rising prevalence of heart valve diseases, particularly in the aging population, is driving the demand for transcatheter heart valve (THV) procedures, such as TAVR, especially for conditions such as aortic stenosis and mitral regurgitation.
Key factors propelling the growth of the transcatheter heart valve industry include continuous improvements in THV design, advancements in imaging and delivery systems, and the increasing preference for minimally invasive surgeries, which offer shorter recovery times, reduced complications, and lower healthcare costs compared to traditional open-heart surgery.
In September 2024, the CDC reported that 75% of adults in the U.S. have limited knowledge about heart valve disease. This lack of awareness extends to high-risk groups, particularly individuals aged 65 and older. Each year, over 5 million people in the U.S. receive a diagnosis of heart valve disease, contributing to more than 25,000 fatalities attributed to this condition annually.
The growing prevalence of heart valve diseases, particularly in the aging population, significantly drives the demand for transcatheter heart valve (THV) procedures. Conditions such as aortic stenosis and mitral regurgitation are becoming more common, necessitating advanced treatment solutions such as THVs. In September 2024, the CDC reported that 75% of adults in the U.S. have limited knowledge about heart valve disease. This lack of awareness extends to high-risk groups, particularly individuals aged 65 and older. Each year, over 5 million people in the U.S. receive a diagnosis of heart valve disease, contributing to more than 25,000 fatalities attributed to this condition annually.
Continuous improvements in THV design, including enhanced valve durability, ease of implantation, and improved patient outcomes, are crucial drivers. Advancements in imaging techniques and valve delivery systems have also significantly improved procedural success and expanded the patient pool eligible for THV procedures. In August 2024, Boston Scientific announced that its ACURATE Prime Aortic Valve System has received CE mark approval. This state-of-the-art transcatheter aortic valve replacement system features a new valve size to serve patients with larger anatomies and is indicated for individuals at low, intermediate, and high risk experiencing severe aortic stenosis. The system features a self-expanding design and a refined deployment mechanism, enhancing the accuracy of valve positioning to improve overall patient outcomes.
Global Transcatheter Heart Valve Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global transcatheter heart valve market report based on application, technology, and region: